ArticleWorld journal of gastrointestinal oncology2021
Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway.
Article in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Molecular mechanisms and therapeutic strategies: DNA methylation in pancreatic cancer.Cancer biology & therapy · 2026Review
- Combining Phytochemical and Computational Approach on Citrus hystrix DC. (Kaffir Lime) Peel Extract: Anti-Diabetic and Anti-Inflammatory Activities.Chemistry & biodiversity · 2026Article
- Solvent-Dependent Metabolomic Profiles and Antioxidant Properties of the Invasive SeaweedPharmaceuticals (Basel, Switzerland) · 2026Article
- UPLC-MS/MS analysis and bioactivity comparison of wild and cultivatedRSC advances · 2026Article
- Natural simple coumarins and their interaction with AKR1C3: implications for overcoming chemoradioresistance in gastrointestinal carcinomas.Medical oncology (Northwood, London, England) · 2026Article
- Truncated pardaxin derivative D18.13 induces selective breast cancer apoptosis via predicted targeting of MAPK8.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mechanisms of Antiproliferative Effects of Nobiletin, Scoparone, and Tangeretin Isolated fromInternational journal of molecular sciences · 2026Article
- Cancer network pharmacology: multi-network regulatory mechanisms and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Scoparone suppresses proliferation and cell cycle of hepatocellular carcinoma cells via inhibiting AKT/GSK-3β/cyclin D1 signaling pathway.Translational cancer research · 2025Article
- Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.Molecular cancer · 2024Review
- SPDEF drives pancreatic adenocarcinoma progression via transcriptional upregulation ofBiomolecules & biomedicine · 2024Article
- Article
- Isoscopoletin inhibits hepatocellular carcinoma cell proliferation via regulating glycolysis-related proteins.PloS one · 2024Article
- Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation.Animal cells and systems · 2024Article
- CIP2A interacts with AKT1 to promote the malignant biological behaviors of oral squamous cell carcinoma by upregulating the GSK‑3β/β‑catenin pathway.Experimental and therapeutic medicine · 2023Article
- Scoparone inhibits breast cancer cell viability through the NF‑κB signaling pathway.Experimental and therapeutic medicine · 2023Article
- Review
- SEdb 2.0: a comprehensive super-enhancer database of human and mouse.Nucleic acids research · 2023Article
- Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Identification of Molecular Targets and Underlying Mechanisms of Xiaoji Recipe against Pancreatic Cancer Based on Network Pharmacology.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is a highly malignant tumor of the gastrointestinal system whose emerging resistance to chemotherapy has necessitated the development of novel antitumor treatments. Scoparone, a traditional Chinese medicine monomer with a wide range of pharmacological properties, has attracted considerable attention for its antitumor activity.
aimTo explore the potential antitumor effect of scoparone on pancreatic cancer and the possible molecular mechanism of action.
methodsThe target genes of scoparone were determined using both the bioinformatics and multiplatform analyses. The effect of scoparone on pancreatic cancer cell proliferation, migration, invasion, cell cycle, and apoptosis was detected
resultsThe hub genes involved in the suppression of pancreatic cancer by scoparone were obtained by network bioinformatics analyses using publicly available databases and platforms, including SwissTargetPrediction, STITCH, GeneCards, CTD, STRING, WebGestalt, Cytoscape, and Gepia;
conclusionOur findings indicate that scoparone inhibits pancreatic cancer cell proliferation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.